Active, not recruitingPhase 3NCT00980460
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
Studying Hepatoblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Howard M Katzenstein, MDChildren's Oncology Group
- Intervention
- Cisplatin(drug)
- Enrollment
- 236 target
- Eligibility
- 21 years · All sexes
- Timeline
- 2009 – 2026
Study locations (30)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- USA Health Strada Patient Care Center, Mobile, Alabama, United States
- Phoenix Childrens Hospital, Phoenix, Arizona, United States
- Banner University Medical Center - Tucson, Tucson, Arizona, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Kaiser Permanente Downey Medical Center, Downey, California, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Cedars Sinai Medical Center, Los Angeles, California, United States
- Valley Children's Hospital, Madera, California, United States
- UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
- Kaiser Permanente-Oakland, Oakland, California, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00980460 on ClinicalTrials.govOther trials for Hepatoblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07188311Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in ChildrenSun Yat-sen University
- RECRUITINGNCT05556642Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium InitiativeChildren's Hospital Medical Center, Cincinnati
- RECRUITINGPHASE1, PHASE2NCT04634357ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular CarcinomaEureka Therapeutics Inc.
- RECRUITINGPHASE2NCT07300449A Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and Monitoring the Recurrence and Metastasis of Hepatoblastoma in Children and AdolescentsSun Yat-sen University
- RECRUITINGPHASE1, PHASE2NCT04901702Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing SarcomaSt. Jude Children's Research Hospital
- RECRUITINGPHASE3NCT04478292A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT StrategyShanghai Children's Medical Center
- ACTIVE NOT RECRUITINGPHASE3NCT03017326Paediatric Hepatic International Tumour TrialUniversity of Birmingham